Aim Immunotech Stock Five Year Return
| AIM Stock | USD 0.22 0.01 4.29% |
AIM ImmunoTech fundamentals help investors to digest information that contributes to AIM ImmunoTech's financial success or failures. It also enables traders to predict the movement of AIM Stock. The fundamental analysis module provides a way to measure AIM ImmunoTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AIM ImmunoTech stock.
AIM | Five Year Return |
AIM ImmunoTech Company Five Year Return Analysis
AIM ImmunoTech's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
AIM Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for AIM ImmunoTech is extremely important. It helps to project a fair market value of AIM Stock properly, considering its historical fundamentals such as Five Year Return. Since AIM ImmunoTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AIM ImmunoTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AIM ImmunoTech's interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
AIM Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, AIM ImmunoTech has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
AIM Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AIM ImmunoTech's direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics of similar companies.AIM ImmunoTech is currently under evaluation in five year return category among its peers.
AIM Fundamentals
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 9.61 M | ||||
| Shares Outstanding | 63.71 M | ||||
| Shares Owned By Insiders | 8.57 % | ||||
| Shares Owned By Institutions | 14.07 % | ||||
| Number Of Shares Shorted | 491.37 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 4.60 X | ||||
| Price To Sales | 66.73 X | ||||
| Revenue | 202 K | ||||
| Gross Profit | (715 K) | ||||
| EBITDA | (31.68 M) | ||||
| Net Income | (28.96 M) | ||||
| Cash And Equivalents | 27.05 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 718 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (21.27 M) | ||||
| Short Ratio | 1.63 X | ||||
| Earnings Per Share | (0.47) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 2.75 | ||||
| Number Of Employees | 26 | ||||
| Beta | -0.36 | ||||
| Market Capitalization | 13.41 M | ||||
| Total Asset | 19.38 M | ||||
| Retained Earnings | (409.51 M) | ||||
| Working Capital | 34.96 M | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 19.38 M |
About AIM ImmunoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out AIM ImmunoTech Piotroski F Score and AIM ImmunoTech Altman Z Score analysis. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.